Format

Send to

Choose Destination
Clin Infect Dis. 2019 Oct 11. pii: ciz991. doi: 10.1093/cid/ciz991. [Epub ahead of print]

Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in OPAT.

Author information

1
Division of Infection, University College London Hospitals, UK.
2
Clinical Research Department, London School of Hygiene and Tropical Medicine, United Kingdom.
3
Department of Clinical Microbiology, University College London Hospitals, UK.
4
Division of Infection & Immunity, University College London, UK.

Abstract

The OVIVA study demonstrated non-inferiority for managing bone and joint infections (BJI) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJI at our centre would be eligible for oral antibiotics, saving median 19.5 IV antibiotic days (IQR 8.5-37) and GBP 1,234 (IQR 569-2,594) per patient.

KEYWORDS:

IV antibiotics; OPAT; OVIVA

PMID:
31603189
DOI:
10.1093/cid/ciz991

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center